Philip Shettle, DO
Ophthalmology · Largo, FLNPI 1023016243
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,219 of the $6,337 with a category attached, or 66.6%. 18 manufacturers reported payments, led by Vertical Pharmaceuticals, LLC at 31.6% of the total. Reporting peaked in 2019 at $2,584 and has fallen 52.2% since, to $1,236 in 2025.
Across 107 payments — averaging $59.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertical Pharmaceuticals, LLC$2K
- Bausch & Lomb Americas Inc.$1K
- Mallinckrodt Hospital Products Inc.$1K
- Sun Pharmaceutical Industries Inc.$480
- Novartis$384
- Eyevance Pharmaceuticals LLC$180
- plus $825 from 12 others
Across 112 payments — averaging $14,183 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$841K
- Oyster Point Pharma, Inc.$194K
- Ocular Therapeutix, Inc.$192K
- Bausch Health US, LLC$146K
- Glaukos Corporation$78K
- Kala Pharmaceuticals, Inc.$51K
- plus $87K from 6 others
What the payments were for
- Consulting fees$2,00032%
- Travel & lodging$1182%
- Food & beverage$4,21967%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertical Pharmaceuticals, LLC | 1 | $2,000 |
| Bausch & Lomb Americas Inc. | 21 | $1,390 |
| Mallinckrodt Hospital Products Inc. | 32 | $1,079 |
| Sun Pharmaceutical Industries Inc. | 15 | $480 |
| Novartis | 8 | $384 |
| Eyevance Pharmaceuticals LLC | 5 | $180 |
| AbbVie(2 entities) | 4 | $176 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $125 |
| Amgen | 1 | $121 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $107 |
| Coopervision Inc. | 5 | $96 |
| Dompe US, Inc. | 2 | $63 |
| Glaukos Corporation | 1 | $38 |
| Aerie Pharmaceuticals, Inc. | 1 | $24 |
| Harrow Eye, LLC | 1 | $20 |
| Alcon | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $19 |
| Oyster Point Pharma, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$593
- XIIDRA$491
- CEQUA$248
- Catalys Laser System$125
- Tecnis Symfony IOL$125
- VYZULTA$125
- ACTHAR$125
- INFUSE MULTIFOCAL$125
- VUITY$124
- TEPEZZA$121
- Zerviate$112
How this compares
$6,337 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 39 | $48,240 |
| CequaCyclosporine | 22 | $18,615 |
| LumiganBimatoprost | 30 | $11,966 |
| VevyeCyclosporine | 11 | $10,559 |
| XiidraLifitegrast | 11 | $8,936 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $7,480 |
| Cyclosporine | 11 | $6,527 |
| Latanoprost | 419 | $4,818 |
| Timolol Maleate | 99 | $2,923 |
| Brimonidine Tartrate | 41 | $2,012 |
| Prednisolone Acetate | 65 | $1,840 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 47 | $836 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 68 | $684 |
| MoxifloxacinMoxifloxacin Hcl | 31 | $522 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 16 | $520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $176 | $60,20669 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $480 | $18,61522 claims |
| Harrow Eye, LLCVevye | $20 | $10,55911 claims |
| Bausch & Lomb Americas Inc.Xiidra | $1,390 | $8,93611 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $24 | $7,48014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Largo
- Neel DesaiLargo$1M
- Robert WeinstockLargo$605K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.